Bearman S I, Shpall E J, Jones R B, Cagnoni P J, Ross M
Bone Marrow Transplant Program, University of Colorado Health Sciences Center, Denver, 80262, USA.
Semin Oncol. 1996 Feb;23(1 Suppl 2):60-7.
High-dose chemotherapy (HDCT) is being evaluated in the treatment of metastatic and high-risk primary breast cancer. The actuarial 2-year disease-free survival rate for patients with stage IV breast cancer is approximately 15% to 20%. A single metastatic site and achievement of a complete response to induction chemotherapy may be favorable prognostic indicators for disease-free survival after HDCT. Phase II studies in patients with primary breast cancer and > or = 10 and four to nine involved axillary nodes are encouraging. Prospective randomized trials are ongoing in these patient groups. Various strategies are being investigated to reduce the incidence of relapse after HDCT.
大剂量化疗（HDCT）正在用于转移性和高危原发性乳腺癌的治疗评估。IV期乳腺癌患者的精算2年无病生存率约为15%至20%。单个转移部位以及诱导化疗获得完全缓解可能是HDCT后无病生存的有利预后指标。对原发性乳腺癌且腋窝淋巴结受累≥10个以及4至9个的患者进行的II期研究结果令人鼓舞。针对这些患者群体的前瞻性随机试验正在进行中。目前正在研究各种策略以降低HDCT后复发的发生率。
